Showing results (181-190 of 205) with videos related to
Sort By:
Pageof 21
Cell Research|September 21, 2011
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNALin Zhang, Dongxia Hou, Xi Chen, et al.Chinese Journal of Cancer|December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumabMasahito Kotaka, Ruihua Xu, Kei Muro, et al.Cell Research|September 4, 2008
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesXi Chen, Yi Ba, Lijia Ma, et al.The Lancet. Oncology|May 17, 2020
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyJing Huang, Jianming Xu, Yun Chen, et al.Journal of Hematology & Oncology|February 7, 2025
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trialGang Chen, Dong-Chen Sun, Yi Ba, et al.JAMA|September 14, 2021
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical TrialHuiyan Luo, Jin Lu, Yuxian Bai, et al.Cell Reports. Medicine|October 4, 2025
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b studyYuxiang Ma, Shaoyan Lin, Qun Chen, et al.Med (New York, N.Y.)|June 13, 2024
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trialMingming He, Zhiqiang Wang, Jin Lu, et al.Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal JunctionJin Li, Shukui Qin, Jianming Xu, et al.Pageof 21